Please Wait
Applying Filters...
Menu

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-94027.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-38847.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-45234.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-69296.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-49289.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-15148.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-58948.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-1627536207.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-1627536144.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-1627536085.pdf

    https://www.pharmacompass.com/pdf/party/content/sharp-party-content-1627535592.pdf

COMPANY BIO #AboutSupplier

read-more
read-more
Sharp | Pharmaceutical Packaging | Contract  Packaging
Sharp | Pharmaceutical Packaging | Contract Packaging
View Sharp's contract pharmaceutical packaging services, including primary packaging & secondary packaging services on PharmaCompass.  How do Sharp’s capabilities and global expertise establish it as a leader in pharmaceutical packagi...
#LearnMore
November, 2025
Share Share
Sharp | Pharmaceutical Packaging | Contract  Packaging
View Sharp's contract pharmaceutical packaging services, including primary packaging & secondary packaging services on PharmaCompass.  How do Sharp’s capabilities and global expertise establish it as a leader in pharmaceutical packaging? Sharp has positioned itself as a leader in pharmaceutical packaging by offering end‑to‑end commercial solutions that span primary packaging services and secondary packaging services. With facilities strategically located in the US, UK, and EU, Sharp provides innovative, scalable pharma packaging solutions for a wide range of dosage forms, including oral solids and injectables Their expertise covers pharmaceutical packaging design, serialization, aggregation, and sustainable pharma packaging, enabling them to manage complex regulatory requirements while ensuring quality, safety, and efficiency. By integrating global expertise with advanced technologies, Sharp supports pharmaceutical and biotech clients from clinical stages through commercial launch, making them a trusted partner in contract packaging. Sharp offers an extensive range of formats from bottles, blisters, pouches, and sachets while specializing in complex requirements such as cold‑chain labeling, clinical trial blinding, and sterile manufacturing. This breadth allows Sharp to serve both small clinical batches and large‑scale commercial volumes with speed, flexibility, and reliability. By combining global reach, regulatory expertise, and technical versatility, Sharp delivers innovative, right‑first‑time solutions that reduce risk and accelerate market entry, reinforcing its reputation as a trusted provider of contract pharma packaging services, contract packaging, and both primary packaging services and secondary packaging services worldwide. How does Sharp ensure global serialization and aggregation compliance? Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing with a heritage spanning more than 70 years. In the field of pharmaceutical packaging, Sharp ensures full compliance with global serialization and aggregation requirements by combining deep domain expertise and robust technologies for primary packaging and secondary packaging services. Their serialization practice dates back to 2007, and their team of specialists in engineering, design, quality, validation, and project management deliver reliable, regulatory‑compliant traceability across both primary packaging and secondary packaging operations. To manage the complexity of track‑and‑trace regulations, Sharp maintains a flexible, interoperable architecture that supports various regional frameworks. Powerful traceability systems integrated with pharmaceutical packaging lines apply unique serial numbers and manage aggregation data, ensuring every unit, case, and pallet is fully trackable. By applying proven, uniform methods across global sites, Sharp minimizes complexity and reduces implementation timelines for clients seeking pharmaceutical contract packaging services. Their scalable GMP facilities, serialization‑ready lines, and standardized vendor platforms reduce integration risks, simplify data exchange, and ensure consistent compliance across markets. In short, Sharp’s expertise in contract packaging, pharmaceutical packaging, and pharma packaging combined with decades of serialization leadership guarantees compliance and reliability. By embedding serialization and aggregation into every primary packaging and secondary packaging operation, Sharp strengthens supply chain visibility and establishes itself as a trusted partner in pharmaceutical contract packaging services worldwide. What are the key packaging challenges in the pharmaceutical industry, and how does Sharp address them? In the pharmaceutical packaging industry, pharma packaging faces multiple complex challenges from ensuring patient safety and regulatory compliance to optimizing logistics, sustainability, and usability. Sharp addresses these with specialized expertise and innovative solutions. Complex secondary packaging services design: Pharmaceutical Packaging formats like blister carding, tertiary trays, shipper design, and kitting involve a wide variety of materials and configurations. Sharp’s design team composed of structural engineers, graphic designers, and regulatory experts can navigate this complexity to deliver contract packaging that is both high‑quality and efficient. Sustainability and Protection: Pharmaceutical industry is increasingly adopting eco‑friendly materials, but many of these newer materials pose design and cost challenges. Sharp’s Sustainable Materials Innovation Group explores alternatives like recycled thermoform plastics, mono‑material cardboards, and biodegradable PaperFoam®, validating these for sterility and stability without compromising patient safety. Sharp also tackles challenges like global serialization and aggregation requirements, ensuring every unit is traceable and compliant with DSCSA and EU FMD standards. Their expertise in primary packaging services and secondary packaging services ensures reliability across formats. User‑friendly safety design: Designing packages that are both child‑resistant (CR) and senior‑friendly (SF) is particularly challenging. Sharp’s global design team addresses this by engineering compliant CR/SF packaging in accordance with standards like ISO 8317 and 16 CFR‑1700.20.They also run design iterations and testing, carefully balancing resistance for child safety with usability for older or physically challenged users. Sharp develops child‑resistant formats such as bottles and blister packs that comply with safety regulations yet are easy for adults to use, striking the right balance between protection and accessibility. Patient‑centric usability: Beyond resistance, Sharp prioritizes user experience. For example, in injectables, their designers have developed trays that maintain sterility while allowing easy, ergonomic removal of the device by patients including those with limited dexterity. Logistics and shipping risk: Ensuring that pharma packaging can withstand real‑world transportation is critical. Sharp conducts rigorous shipping studies, simulating vibration, impact, and environmental stress to make sure that pharmaceutical contract packaging services protect the product all the way to the patient.By combining innovation, compliance, and global expertise, Sharp strengthens its role as a trusted leader in contract pharma packaging services, pharma packaging, and pharmaceutical packaging worldwide. What quality systems and GMP standards does Sharp follow in its secondary packaging to ensure reliability and safety? Sharp maintains the highest standards of reliability and safety in its secondary packaging through a comprehensive Pharmaceutical Quality System (PQS) and a cloud-based Quality Management System (QMS) that ensures consistent document control, CAPA management, and process compliance across all its global facilities. Its GMP-certified sites in the US, EU, and UK are regularly inspected and follow validated procedures for vial labeling, cartoning, kitting, and serialization, ensuring adherence to international regulatory requirements. Every process is validated, monitored, and continuously improved to ensure pharma packaging integrity, patient safety, and compliance with international regulatory authorities such as the FDA, EMA, and MHRA By embedding GMP principles into both clinical packaging and commercial packaging, Sharp guarantees reliability and consistency at every stage. Their “right‑first‑time” approach, combined with employee accountability for quality, ensures medicines are packaged safely, traceably, and in full compliance with global standards, reinforcing Sharp’s role as a trusted partner in pharmaceutical packaging services. Sharp’s design and engineering teams work closely with quality and regulatory experts to integrate compliance, usability, and safety into every package. Child-resistant and senior-friendly features, correct component verification, and serialization are carefully embedded into the process. This multi-layered approach allows Sharp to deliver consistent, compliant, and high-quality contract packaging solutions that pharmaceutical companies can trust. By combining expertise in contract pharma packaging, commercial packaging, clinical packaging, and pharmaceutical packaging services, Sharp reinforces its reputation as a global leader in reliable and safe pharma packaging operations.

Impressions: 77

DATA COMPILATION #PharmaFlow

read-more
read-more
Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities
Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 

Impressions: 14739

https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

#PharmaFlow by PHARMACOMPASS
21 Nov 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.sharpservices.com/about-us/news/sharp-appoints-samantha-wilson-jones-as-general-counsel/

PRESS RELEASE
01 Oct 2025

https://www.sharpservices.com/about-us/news/sharp-invests-20-million-in-autoinjector-pen-assembly-lines-to-meet-rising-demand-for-injectables/

PRES RELEASE
02 Sep 2025

https://www.sharpservices.com/about-us/news/sharps-emissions-reduction-targets-validated-by-science-based-targets-initiative/

PRESS RELEASE
15 Jul 2025

https://www.sharpservices.com/about-us/news/berkshire-sterile-manufacturing-llc-rebrands-to-sharp-sterile-manufacturing-llc/

PRESS RELEASE
18 Oct 2024

https://www.sharpservices.com/about-us/news/sharp-joins-the-united-nations-global-compact/

PRESS RELEASE
30 Sep 2024

https://www.sharpservices.com/about-us/news/berkshire-sterile-manufacturing-appoints-new-president/

PRESS RELEASE
28 May 2024